Wednesday, 18 Sep 2019

You are here

Coexistent Gout Increases Risk in Rheumatoid Arthritis

It his often said that gout and rheumatoid arthritis (RA) cannot coexist and where confusion exists, a good history and testing for serum urate (SUA) and rheumatoid factor (RF) can usually clarify the dominant disorders.  A recent study shows that hyperuricemia and gout are uncommon in RA, but when present shows an increased risk of comorbidities and cardiovascular (CV) mortality.

Subjects from the multicenter Veterans Affairs Rheumatoid Arthritis (VARA) registry were included and assessed for the presence of gout and serum urate (sUA) levels. 

From a total of 1,999 RA patients 17% had elevated sUA levels (>6.8 mg/dl) and 6.1% had a diagnosis of gout.

The presence of moderate hyperuricemia (sUA >6.8‐8 mg/dl) was associated with an increased risk of CVD‐related mortality (HR 1.56; 95% CI 1.11‐2.21), but this association was attenuated and became nonsignificant with adjustments for other comorbidities commonly seen with hyperuricemia. There were no associations of baseline sUA with all‐cause mortality.

Thus there is a small subset of RA patients who may have gout or hyperuricemia and such findings should underscore the need to also manage comorbidities that may contribute to cardiovascular risk.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Modifiable Risk Factors for Hyperuricemia

Choi and colleagues have shown that four modifiable risk factors (BMI, the DASH diet, alcohol use, and diuretic use) could individually account for a notable proportion of observed hyperuricemia. 

Researchers examine modifiable risk factors for hyperuricemia and how this could be prevented through risk factor modification in the general population.

Opioids Overused in Acute Gout

Opioids were commonly given to patients as a treatment for acute gout attacks, despite the availability of other effective and appropriate therapies, a retrospective study found.

Allopurinol Fails to Curtail Hypertension

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Allopurinol Fails to Curtail Hypertension

A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Updated 2018 EULAR Recommendations for the Diagnosis of Gout

The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.